BIORA THERAPEUTICS INC (PROG) Stock Fundamental Analysis

NASDAQ:PROG • US74319F1075

0.8845
-0.03 (-3.47%)
At close: May 6, 2022
0.9
+0.02 (+1.75%)
After Hours: 5/6/2022, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

PROG gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 102 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of PROG have multiple concerns. PROG does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year PROG has reported negative net income.
PROG Yearly Net Income VS EBIT VS OCF VS FCFPROG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 -50M -100M -150M -200M

1.2 Ratios

Industry RankSector Rank
ROA -227.32%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PROG Yearly ROA, ROE, ROICPROG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 0 -2K -4K -6K

1.3 Margins

Industry RankSector Rank
OM -517.86%
PM (TTM) -966.06%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PROG Yearly Profit, Operating, Gross MarginsPROG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 0 -5K -10K -15K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, PROG has more shares outstanding
  • PROG has a worse debt/assets ratio than last year.
PROG Yearly Shares OutstandingPROG Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 50M 100M 150M
PROG Yearly Total Debt VS Total AssetsPROG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -12.84, we must say that PROG is in the distress zone and has some risk of bankruptcy.
  • PROG has a Debt/Equity ratio of -1.49. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity -1.49
Debt/FCF N/A
Altman-Z -12.84
ROIC/WACCN/A
WACCN/A
PROG Yearly LT Debt VS Equity VS FCFPROG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 0 100M -100M

2.3 Liquidity

  • PROG has a Current Ratio of 1.60. This is a normal value and indicates that PROG is financially healthy and should not expect problems in meeting its short term obligations.
  • PROG has a Quick Ratio of 1.60. This is a normal value and indicates that PROG is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 1.6
Quick Ratio 1.6
PROG Yearly Current Assets VS Current LiabilitesPROG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • PROG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 68.83%, which is quite impressive.
  • PROG shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -65.54%.
  • The Revenue for PROG have been decreasing by -78.64% on average. This is quite bad
EPS 1Y (TTM)68.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.4%
Revenue 1Y (TTM)-65.54%
Revenue growth 3Y-78.64%
Revenue growth 5YN/A
Sales Q2Q%-96.95%

3.2 Future

  • Based on estimates for the next years, PROG will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.23% on average per year.
  • The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y77.59%
EPS Next 2Y33.26%
EPS Next 3Y20.89%
EPS Next 5Y12.23%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PROG Yearly Revenue VS EstimatesPROG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 50M 100M
PROG Yearly EPS VS EstimatesPROG Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for PROG. In the last year negative earnings were reported.
  • Also next year PROG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PROG Price Earnings VS Forward Price EarningsPROG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -1.53
PROG Per share dataPROG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as PROG's earnings are expected to grow with 20.89% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.26%
EPS Next 3Y20.89%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for PROG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

BIORA THERAPEUTICS INC

NASDAQ:PROG (5/6/2022, 8:00:02 PM)

After market: 0.9 +0.02 (+1.75%)

0.8845

-0.03 (-3.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)05-10
Earnings (Next)08-10
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners8.45%
Ins Owner Change0%
Market Cap162.92M
Revenue(TTM)25.61M
Net Income(TTM)-247.41M
Analysts82.86
Price Target4.08 (361.28%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.36
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA -1.53
EPS(TTM)-2.23
EYN/A
EPS(NY)-0.5
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.14
BVpS-0.46
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -227.32%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -517.86%
PM (TTM) -966.06%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity -1.49
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.6
Quick Ratio 1.6
Altman-Z -12.84
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.4%
EPS Next Y77.59%
EPS Next 2Y33.26%
EPS Next 3Y20.89%
EPS Next 5Y12.23%
Revenue 1Y (TTM)-65.54%
Revenue growth 3Y-78.64%
Revenue growth 5YN/A
Sales Q2Q%-96.95%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

BIORA THERAPEUTICS INC / PROG FAQ

What is the ChartMill fundamental rating of BIORA THERAPEUTICS INC (PROG) stock?

ChartMill assigns a fundamental rating of 2 / 10 to PROG.


What is the valuation status of BIORA THERAPEUTICS INC (PROG) stock?

ChartMill assigns a valuation rating of 0 / 10 to BIORA THERAPEUTICS INC (PROG). This can be considered as Overvalued.


How profitable is BIORA THERAPEUTICS INC (PROG) stock?

BIORA THERAPEUTICS INC (PROG) has a profitability rating of 0 / 10.


What is the financial health of BIORA THERAPEUTICS INC (PROG) stock?

The financial health rating of BIORA THERAPEUTICS INC (PROG) is 3 / 10.